TAF Real World Study for Universal Effectiveness

UnknownOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

January 25, 2019

Primary Completion Date

May 1, 2023

Study Completion Date

September 1, 2023

Conditions
Chronic Hepatitis b
Interventions
DRUG

Tenofovir Alafenamide

The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents

Trial Locations (7)

430030

NOT_YET_RECRUITING

Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Unknown

RECRUITING

Shulan(Hangzhou) hospitai, Hangzhou

RECRUITING

First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

Shanghai public health clinic, Shanghai

NOT_YET_RECRUITING

General Hospital of The Yangtze River Shipping, Wuhan

RECRUITING

The Seventh Hospital of Wuhan, Wuhan

RECRUITING

Xiangya Hospital of Central South University, Xiangya

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Tongji Hospital

OTHER

NCT03752658 - TAF Real World Study for Universal Effectiveness | Biotech Hunter | Biotech Hunter